Ciba Enters Epilepsy Disease Management
Ciba Pharmaceuticals of the USA and Lovelace Healthcare Innovations are to collaborate on a disease management program for the treatment of epilepsy, the firms have announced.
Lovelace will develop an "epilepsy episodes of care program," a comprehensive health care treatment program for the diagnosis and treatment of epilepsy. Ciba will assist by providing outcomes analysis and validation of the program, and will provide educational materials for use in conjunction with Lovelace's disease management guidelines.
Director of pharmaceutical outcomes research for Ciba Pharmaceuticals Diana Brixner said: "Ciba's agreement with Lovelace is a significant step for Ciba and for the managed care community. It marks Ciba's entry into disease management, and it is a program designed to be a true partnership between a pharmaceuticals company and an integrated healthcare system."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze